Here are relevant reports on : pcr-thermocycler-market
-
Companion Animal Diagnostic Market by Product (Consumable, Instrument), Technology (Immunodiagnostic, ELISA, PCR Test, Urinalysis, Hematology), Animal Type (Dog, Cat), Application (Clinical Pathology, Virology), End User - Global Forecast to 2031
The global Companion Animal Diagnostic market, valued at USD 3.29 billion in 2025, stood at USD 3.56 billion in 2026 and is projected to advance at a resilient CAGR of 8.7% from 2026 to 2031, culminating in a forecasted valuation of USD 5.40 billion by the end of the period. Factors driving the companion animal diagnostics market include the rising demand for rapid and accurate diagnostic testing, the rising use of advanced technologies such as molecular diagnostic tests and AI-based analyzers, and also the growing focus on preventive and early diagnostic testing for companion animals.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
US Veterinary Diagnostics Market by Application (Infectious, Bacterial, Endocrine), Technology (Immunodiagnostic, PCR, ELISA, Lateral Flow), Product (Consumables, Instruments), Animal Type (Dog, Cat, Cattle), End User (POC, Veterinary Labs) – Forecast to 2031
The US veterinary diagnostics market, valued at USD2.22 billion in 2025, stood at USD2.41 billion in 2026 and is projected to advance at a resilient CAGR of 9.1% from 2026 to 2031, culminating in a forecasted valuation of USD3.74 billion by the end of the period.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
High-Resolution Melting Analysis Market by Product (Supermix Reagent, RT PCR Instrument, Software), Application (SNP Genotyping, Mutation Discovery, Epigenetics), Enduser (Research Laboratories, Hospital, Diagnostic Center) - Global Forecast to 2021
The global high-resolution melting analysis market is projected to grow at a CAGR of 3.1%. Rising prevalence of infectious diseases and genetic disorders; increasing public-private investments, funds, and grants for research on genetic analysis technologies; and advantages of HRM over other genotyping technologies are the major factors driving market growth.
- Published: April 2017
- Price: $ 4950
- TOC Available:
-
Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) & Geography
The global biomarker technologies market is projected to grow at a CAGR of 9.7%. The key players in the biomarker technologies market are Thermo Fisher Scientific (US), Agilent Technologies (US), Roche (Switzerland), Danaher Corporation (US), Waters Corporation (US), Shimadzu Corporation (Japan), and Bio-Rad Laboratories (US).
- Published: May 2018
- Price: $ 15000
- TOC Available:
-
Hepatitis Testing Market / Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region - Global Forecast to 2026
The global hepatitis testing market growth is primed to transition from $2.8 billion in 2021 to $3.6 billion by 2026, showcasing a strong CAGR of 4.7%. The growth of the global market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Non Invasive Prenatal Testing Market by Product (Consumables, Reagent, Ultrasound, NGS, PCR, Microarray), Services, Method (cfDNA, Biochemical Markers), Application (Aneuploidy, Microdeletion) & End-User (Hospital, Labs) - Global Forecasts to 2029
The global non invasive prenatal testing market, valued at US$6.4 billion in 2023, stood at US$7.2 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$14.1 billion by the end of the period. The primary growth factors propelling this market include spiking investments, incentives, and support from both state governments and private companies, which are driving access to and demand for NIPT technologies.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Laboratory Proficiency Testing Market by Industry (Clinical Diagnostics, Microbiology, Pharmaceutical, Food & Animal Feed, Water, Opioid), Technology (PCR, Cell Culture), and Region; Unmet Needs, Stakeholder & Buying Criteria - Global Forecast to 2028
The global laboratory proficiency testing market, valued at US$1.1 billion in 2022, stood at US$1.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.4% from 2023 to 2028, culminating in a forecasted valuation of US$1.6 billion by the end of the period. The proficiency testing market is projected to experience substantial expansion in the forecasted period due to its mandatory requirement for laboratories operating in various regulated industries like APIAC, CLIA, and CLSI.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
The Asia Pacific biomarkers Market, valued at US$13.51 billion in 2024, stood at US$14.73 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$26.40 billion by the end of the period. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) & Geography
The global breast cancer liquid biopsy market is projected to grow at a CAGR of 23.1%. Factors such as increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the breast cancer liquid biopsy market. The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
